Many of the charitable organizations you may be familiar with including, Patient Services Inc. (PSI), PAN, The Assistance Fund, and the Patient Advocate Foundation (PAF), also have COVID specific funds. These funds vary in amounts and eligibility…
BioMarin has released updates on the ongoing clinical trial program for their investigational gene therapy valoctocogene roxaparvovec, which is intended for the treatment of adults with severe hemophilia A. The therapy employs adeno-associated…
Dear NHF Community,
Over the past weeks, our country has been overwhelmed with emotion—shock, grief, horror, rage, and more—amid the news reports and video footage showing harassment of, and violence against Black Americans. At a time when the…
In response to the COVID-19 pandemic, NHF has produced two new weekly vehicles for information for the bleeding disorders community: the Coping During COVID-19 webinar series, and the NHF Health and Wellness newsletter.
Starting June 1st, both…
Fill out my Wufoo form!
The National Hemophilia Foundation (NHF) would like remind healthcare providers that several online educational opportunities for gene therapy are currently available for continuing education credit.
The first two activities are part of the “…
A paper published in the journal Haemophilia, suggests that clinical expectations for people with hemophilia have remained relatively static for years, falling out of alignment with treatment in the 21st century and its promise of unprecedented…
To all physicians, hematologists, and other healthcare professionals
It has become apparent in the recent weeks that COVID-19 patients with severe disease may develop associated coagulopathy, similar to disseminated intravascular…
On March 11, 2020 the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a global pandemic. Our life and lifestyle have been changed dramatically by the pandemic. You may ask yourself, what exactly is a pandemic? The…